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Abstract
Mutations in the insulin receptor gene cause the inherited insulin resistant syndrome leprechaunism. Patient Atl-1 with
 .leprechaunism was homozygous for the substitution of Arg-86 with Pro R86P in the a subunit of the insulin receptor.
Fibroblasts homozygous for the mutant receptor had defective insulin binding, but increased glucose transport and receptor
kinase activity. The R86P mutation is located in a putative b turn N-terminal to a proposed insulin binding domain of the
w  . xreceptor P. DeMeyts, J.-L. Gu, R.M. Shymko, B.E. Kaplan, G.I. Bell, J. Whittaker, Mol. Endocrinol. 4 1990 409–416 .
To get further insight into the mechanism of the paradoxical activation of receptor signalling by the R86P mutation, the
codons for proline, alanine, and glycine were substituted in the R86 position of the insulin receptor cDNA by PCR-mediated
 .mutagenesis and stably transfected into Chinese hamster ovary CHO cells. Insulin binding increased 10–20 fold in CHO
cells transfected with the wild type, the R86A, and the R86G insulin receptor cDNA, but did not increase in cells expressing
the R86P mutation. The R86P mutation caused a constitutive activation of insulin receptor phosphorylation in CHO cells,
but did not increase basal glucose transport or its sensitivity to insulin stimulation. By contrast, transfection with the wild
type and the R86A receptors increased 20–30 fold the sensitivity of glucose transport to stimulation by insulin. The R86G
insulin receptor bound insulin normally, but was four times less efficient than the wild type or R86A insulin receptor in
increasing the sensitivity for insulin stimulation of glucose transport. These results indicate that position 86 of the insulin
receptor a subunit is tolerant to substitution by alanine, but not by proline. Substitution with glycine allows insulin binding,
but does not activate normally glucose transport, further supporting an essential role of this position in the initiation of
insulin receptor signalling of glucose transport. q 1998 Elsevier Science B.V.
Keywords: Insulin receptor; Insulin resistance; Glucose transport; Insulin binding; Leprechaunism
1. Introduction
The first step in insulin action is the binding of the
hormone to specific receptors on the plasma mem-
Abbreviations: CHO, Chinese hamster ovary; IR, insulin re-
ceptor; OMG, 3-O-methyl-D-glucose; WT, wild type
) Corresponding author. Fax: q1-404-727-5783; E-mail:
nl@rw.ped.emory.edu
brane of target cells. The insulin receptor is a hetero-
tetramer composed of two a and two b subunits,
w xlinked by disulfide bonds 1,2 . Insulin binding to the
a subunit activates b subunit autophosphorylation
and kinase activity. Insulin receptor kinase activity is
essential for transmembrane signalling of glucose
w xtransport and other insulin-stimulated functions 3 .
Both subunits of the insulin receptor are encoded by
w xa single gene located on chromosome 19 4 .
The X-ray crystal structure of the tyrosine kinase
0167-4889r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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of the insulin receptor was recently determined and
revealed a novel autoinhibition mechanism, with por-
tions of the receptor b subunit preventing substrate
w xbinding 5 . The autoinhibitory mechanism of the
insulin receptor appears much stronger than that of
the kinase domain of the Fibroblast Growth Factor
w xReceptor 6 , a monomeric tyrosine–kinase receptor
that, unlike the insulin receptor, undergoes ligand-de-
pendent dimerization. It has been speculated that the
dimeric structure of the insulin receptor requires a
stronger autoinhibitory mechanism to prevent kinase
w xautoactivation 6 . Insulin binding to the extracellular
a subunit may release autoinhibition and activate
receptor signalling. This hypothesis is supported by
studies showing that removal of the a subunit by
w x w xproteolysis 7 or mutagenesis 8,9 activates the re-
ceptor kinase.
The structure of the insulin receptor a subunit has
not yet been determined by X-ray analysis. However,
the study of natural and artificial mutations in the
insulin receptor has defined different regions of the a
subunit which are needed to form a high-affinity
w xinsulin binding site 10 . These regions include the
N-terminus with a domain rich in aromatic residues
w x w x11 , the cysteine-rich region 12,13 , a second do-
w xmain rich in aromatic residues 14 , and the C-termi-
w xnal region 15 . A model for their organization has
been provided, with the two aromatic regions forming
the binding surface interacting with the A and B
w xchain of insulin 14 .
Natural mutations in the insulin receptor gene
cause the autosomal recessive disorders leprechau-
nism and Rabson–Mendenhall syndrome, which are
characterized by intrauterine growth restriction, dys-
morphic features, absence of subcutaneous fat, and
w xsevere insulin-resistance 16,17 . Fibroblasts obtained
from most patients with leprechaunism have defec-
tive insulin binding and consequently defective in-
sulin stimulation of receptor phosphorylation and glu-
w xcose transport 18–21 . An exception to this rule is
represented by fibroblasts obtained from patient Atl-1
with leprechaunism, which have defective insulin
w xbinding 22 , but a constitutive increase in receptor
w x w xphosphorylation 4 and glucose transport 23 . This
patient was homozygous for a point mutation con-
 . w xverting the codon for Arg-86 to Pro R86P 24 .
Computer modeling of the insulin receptor according
to the crystal structure of insulin suggests that Arg-86
is located in a b turn prior to the b sheet formed by
a stretch of aromatic amino acids in the N-terminal
w xportion of the insulin receptor 11,25 . Phe-89, down-
stream from the R86P substitution, has been proposed
to play a key role in binding the B chain of insulin
w x11 . The importance of this portion of the insulin
receptor in insulin binding is further supported by
another natural mutation substituting Pro for Leu-87,
which greatly impairs insulin binding, but results in
decreased, rather than increased receptor phosphory-
w xlation 26 .
Activation of receptor phosphorylation has been
observed with other natural mutations in the insulin
receptor a subunit. Removal of Lys-121 by a 3-bp
deletion increases basal receptor phosphorylation and
blunts subsequent responses to insulin in transfected
 . w xChinese hamster ovary CHO cells 27 . This muta-
tion, however, does not directly affect insulin binding
w x w x27 , even if it affects negative cooperativity 28 ,
suggesting that the Lys-121 deletion is located near,
w xbut not in the insulin binding site 27,28 . By con-
trast, removal of Asn-281 by a 3-bp deletion abol-
ishes insulin binding and activates basal receptor
w xphosphorylation in cultured fibroblasts 29 . The in-
creased phosphorylation, however does not increase
w xeither DNA or glycogen synthesis 29 . Studies of
fibroblasts from another patient with the same dele-
tion also revealed normal basal glucose and amino
w x .acid transport 30 , unpublished results , indicating
w xthat this mutation, unlike the R86P substitution 22
was not associated with stimulation of any known
biological function regulated by the insulin receptor.
To gain further insight on the mechanism by which
the R86P substitution abolishes insulin binding and
 .activates glucose transport, we substituted Ala R86A
 .and Gly R86G in position 86 of the human insulin
receptor and evaluated their effect on insulin binding,
receptor phosphorylation and signalling of glucose
transport. Previous studies have shown that substitu-
tion of position 86 with lysine or asparagine did not
w xhave any major effect on insulin binding 31 . The
results presented here indicate that although neither
Ala nor Gly decreased insulin binding, the Gly substi-
 .tution R86G increased the amount of insulin bound
required to stimulate glucose transport. These results
further support an essential role of this region of the
insulin receptor in insulin binding and stimulation of
glucose transport.
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2. Materials and methods
2.1. Materials
Sera, growth media, antibiotics and trypsin were
 .obtained from Whittaker Walkersville MD . 3-O-
w 3 x w125 xmethyl- H -D-glucose and Na I were from New
 .England Nuclear. Sodium porcine insulin 25 Urmg
was from Calbiochem. Insulin was iodinated by chlo-
w xramine T as previously described 22 . Restriction
enzymes and other products for molecular biology
were from Boehringer Mannheim. Monoclonal anti-
bodies against phosphotyrosine were obtained from
Transduction Laboratories. Monoclonal antibody 83-7
against the insulin receptor was a gift of Dr. Jeffrey
 .Pessin. Geneticin G418 sulfate was from Gibco.
Sigma was the source of other chemicals. CHO-K1
cells were obtained from the American Type Culture
Collection and grown in Ham F12 medium supple-
mented with 6% fetal bovine serum in the presence
of penicillin and streptomycin. Culture conditions
were: pH 7.4, temperature 378C, CO 5%.2
2.2. Mutagenesis of the insulin receptor cDNA
The pNEO-IR expression vector was constructed
w xfrom plasmids pcDV 1 and pL2 32 and from the
w xinsulin receptor cDNA 1 as previously described
w x24,33 . It contained both the neomycin-resistance
gene and the insulin receptor cDNA under control of
two separate SV40 early promoters. The R86P muta-
tion was inserted by swapping the EcoRV-XmaI frag-
ment of the insulin receptor cDNA with the same
fragment from PCR amplified exon 2 of the insulin
w xreceptor gene from patient Atl-1 24 . The presence
and uniqueness of the R86P-mutation in the resulting
insulin receptor cDNA was confirmed by sequencing.
Additional mutations were introduced by swapping
the EcoRV-XmaI fragment of the wild type insulin
receptor cDNA with the same fragment mutagenized
in a pGEM vector using overlapping mutant PCR
w xprimers containing the codons for Ala or Gly 34 .
The sequence of the mutagenized expression vector
was verified by sequencing. Normal and mutant plas-
mids were linearized by HindIII-digestion and trans-
fected into CHO cells by electroporation. Transfected
cells were selected for 3 weeks in Ham-F12 contain-
ing 0.8 mgrml of geneticin. Northern blot analysis
was used to confirm expression of the trans-gene
w x24,33 . CPM corresponding to bands on Northern
blots were measured by a Packard Instant Imager.
2.3. Insulin binding
Confluent cells were incubated in 24-well plates
 .Costar for 2 h at 208C or for 16 h at 48C with
125  .I-insulin 250–350 nCirng in 1 ml of TRIS-
buffered Earle’s balanced salt solution. At the end of
the incubation period, cell monolayers were washed
four times with ice-cold saline. Cell monolayers were
then solubilized in 0.4 ml of 1 N NaOH and counted
in a g-counter. After counting, each tube was evalu-
ated for protein content using a modified Lowry
w xprocedure 35 . Insulin binding was normalized to
cell protein and corrected for nonspecific binding
 .measured in the presence of 1 mM cold insulin to
obtain specific binding. Kinetics of insulin binding
were measured for 16 h at 48C to avoid ligand
internalization and degradation. Nonspecific insulin
binding at 48C represented less than 15% of total
binding in both parental CHO cells, cells transfected
with the neomycin-resistance gene or the R86P muta-
tion. Nonspecific binding was negligible less than
.3% of total in cells expressing the other human
insulin receptor cDNAs. The dose of insulin produc-
ing half-maximal inhibition of binding was deter-
mined by nonlinear regression analysis as described
w xpreviously 33 .
2.4. Glucose transport
Cells were plated into 24-well plates and grown to
confluence. The day before the experiment, cells
were refed with fresh medium containing 1% fetal
bovine serum. Cells were washed and incubated for 3
h at 378C in Earle’s balanced salt solution supple-
mented with 0.2% bovine serum albumin in the
absence of serum. Increasing concentrations of in-
sulin were then added for 30 min. The initial rate of
w3 x entry of 3-O-methyl H -D-glucose OMG, 1 mM, 4
. w xmCirml was then measured for 15 s 36 . Cells were
then washed three times with ice-cold 0.1 M MgCl .2
Intracellular radioactivity was extracted with 0.5 ml
of ethanol and counted in a Beckman LS7500 scintil-
lation spectrometer. The cell monolayer was solubi-
lized in 200 ml of 1 N NaOH and evaluated for
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w xprotein 10 . OMG uptake was corrected for cellular
protein and normalized to intracellular water, calcu-
w xlated from the equilibrium distribution of OMG 36 .
Dose–response curves were analyzed according to
the equation
E ) Insulinmax
˝sV q 1 .0 ED q Insulin50
where ˝ is the measured velocity of sugar influx, V0
is the velocity in the absence of insulin, E is themax
maximal stimulation, and ED the concentration of50
insulin at which half-maximal stimulation is observed
w x37 .
2.5. Tyrosine phosphorylation
Cells were incubated for 20 min in Ham F12 in the
 .absence or in the presence of insulin 200 nM . Cells
were then washed twice with ice-cold PBS and lysed
in the presence of kinase and phosphatase inhibitors
w x38 . The suspension was clarified by centrifugation
at 48C, and 100 mg of protein in the supernatant were
separated by SDS-PAGE in reducing conditions di-
.thiothreitol 100 mM . Proteins were blotted to a
 .polyvinylidene difluoride membrane Millipore and
phosphotyrosine identified by a monoclonal anti-
phosphotyrosine antibody PY20 from Signal Trans-
.duction Laboratories . Densitometric analysis of blots
was performed by an Alpha Imager 2000 Documenta-
tion and Analysis System.
Tyrosine phosphorylation of the insulin receptor
was measured with a similar procedure, except that
lysates were immunoprecipitated with the mono-
clonal antibody 83-7 prior to SDS-PAGE and blot-
ting.
3. Results
Transfection of CHO cells with the Wild-Type
 .WT , the R86A, and the R86G IR-cDNAs increased
insulin binding up to 20-fold, without changing sub-
stantially the dose of insulin at which half maximal
binding inhibition by unlabeled insulin was observed
 .Fig. 1, Table 1 . By contrast, transfection with the
R86P mutant cDNA did not increase insulin binding,
confirming that this mutation abolishes insulin bind-
Fig. 1. Insulin binding to CHO cells transfected with normal and
R86-mutant insulin receptor cDNA. Cells were stably transfected
with a plasmid containing the Neomycin-resistant gene and the
insulin receptor cDNA under control of the SV40 early promoter.
Insulin binding was measured for 16 h at 48C. Points are means
"SE of triplicates. The experiment was repeated three times with
similar results.
ing. Densitometric analysis of Northern blots indi-
cated that cells transfected with the WT and R86A
receptors had similar levels of insulin receptor mRNA
 .100 and 95 arbitrary units, respectively , whereas the
R86G cells had about 44% of the insulin receptor
 .mRNA levels measured in these cells not shown .
Thus, there was correlation between expression of the
transgene and insulin binding in CHO cells other than
the R86P transfectants.
Human fibroblasts homozygous for the R86P mu-
tation have a constitutive increase in receptor phos-
w xphorylation and kinase activity 23 . Transfection of
the R86P-mutant insulin receptor in Baby hamster
kidney cells increased the phosphorylation not only
of a 95 kDa band corresponding to the receptor b
subunit, but also of a 200 kDa band, possibly the
w xuncleaved ab proreceptor 31 . We evaluated insulin
stimulation of tyrosine phosphorylation in CHO cells
transfected with the normal and R86-mutant receptors
 .Fig. 2 . Previous studies have shown that insulin
stimulation of CHO cells in vivo results not only in
the phosphorylation of the b subunit of the receptor
but also in the phosphorylation of high molecular
w xweight substrates of the insulin receptor 33 , initially
( )N. Longo et al.rBiochimica et Biophysica Acta 1402 1998 86–9490
Table 1
Insulin binding and glucose transport by CHO cells expressing normal and R86-mutant human insulin receptors
 .Insulin binding Half-maximal Basal OMG influx ED pM Insulin bound at ED50 50
 .  .  .  .fmolrmg protein inhibition nM nmolrmlrs fmolrmg protein
CHO-NEO 3.2"0.2 0.89"0.10 16.0"2.0 285"115 7.8
CHO-WT-IR 63.2"2.4 0.61"0.07 16.0"1.5 9.7"3.4 5.9
CHO-R86P 1.9"0.3 1.12"0.28 13.3"0.5 647"160 13.3
CHO-R86A 58.0"2.0 1.13"0.12 9.7"1.0 12"3.4 7.4
CHO-R86G 23.0"1.7 0.48"0.07 11.8"0.2 127"36 30.3
CHO cells were transfected with pNEO-IR coding for the normal insulin receptor and the R86P, R86A, and R86G amino acid
 .  .substitutions. After selection for 3 weeks with Geneticin G418, 0.8 mgrml , insulin 0.5 ngrml binding was measured for 16 h at 48C
 .in the absence or presence of increasing concentrations of cold insulin 0.001–100 nM . Non-specific binding was measured in the
presence of 1 mM cold insulin and was subtracted from each point.
 .  .3-O-Methyl-D-glucose OMG, 1 mM transport was measured for 15 s in cells incubated for 30 min in the absence basal or in the
 .presence of increasing concentrations 0.001–1000 nM of insulin. The ED was calculated by nonlinear regression of stimulated OMG50
 .influx according to Eq. 1 in Section 2.4 and are expressed as means"95% confidence intervals. The amount of insulin bound at the
measured ED was estimated by computer using binding data obtained within the same experiment. Points are means"SE of triplicates50
within a single experiment. The experiment was repeated twice with similar results.
designated pp185 for their electrophoretic mobility
w x 39 . Two of these substrates Insulin receptor sub-
.strate 1 and Insulin receptor substrate 2 were re-
cently characterized in molecular detail and are be-
lieved to mediate the pleiotropic action of insulin
w x40,41 . In cells transfected with the normal insulin
receptor, insulin increased the phosphorylation of a
95 kDa band, corresponding to the receptor b sub-
unit, and of a high molecular weight band, corre-
 .sponding to pp185 lanes 3,4,11,12 . Only insulin-
stimulated phosphorylation of the high molecular
weight band was evident in cells transfected with the
 .resistance marker alone lanes 1,2,9,10 . Transfection
with the R86A and R86G receptor increased insulin-
stimulated tyrosine phosphorylation of the receptor b
subunit and, to a lesser extent, of high molecular
 .weight substrates pp185 similarly to transfection
 .with the wild type receptor lanes 7,8,13,14 . How-
ever, densitometric analysis of the blot shown in Fig.
2 revealed that phosphorylation of the b subunit of
the receptor was reduced in R86G cells and repre-
sented about 50% of that measured in cells express-
 .ing the WT receptor Fig. 3 . This again correlated
 .with the reduced amounts of insulin binding Fig. 1
and insulin receptor mRNA levels. By contrast, in-
sulin stimulation of tyrosine phosphorylation of pp185
Fig. 2. Effect of insulin on tyrosine phosphorylation in cells expressing normal and mutant insulin receptors. CHO cells were incubated
 .for 20 min in the absence or presence of insulin 200 nM . Cells were then solubilized in the presence of kinase and phosphatase
inhibitors, clarified by centrifugation, separated by SDS-PAGE, blotted to a polyvinylidene difluoride membrane, and phosphotyrosine
detected using the PY20 monoclonal antibody. The experiment was repeated twice with similar results.
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Fig. 3. Densitometric analysis of insulin-stimulated tyrosine
phosphorylation in CHO cells expressing normal and mutant
insulin receptors. Two-dimensional densitometric analysis of the
experiment shown in Fig. 2 was performed with an Alpha Imager
2000 Documentation and analysis system.
was essentially identical among WT-IR, R86A, and
 .R86G cells Fig. 3, panel B .
Transfection of CHO cells with the R86P-mutant
receptor was not accompanied by increased tyrosine
phosphorylation of the receptor b subunit Fig. 2,
.lanes 5,6 . This was in apparent contrast with human
fibroblasts, in which homozygosity for the mutant
receptor results in constitutive activation of b sub-
w xunit phosphorylation 23 . However, the behavior of
the R86P-mutant receptor is different in CHO cells as
compared to diploid fibroblasts. Fibroblasts homozy-
gous for the R86P mutation produce mature insulin
receptors with no increased presence of uncleaved
w xab proreceptor 42 . By contrast, CHO cells trans-
fected with the R86P-mutant receptor produce an
w xexcess of ab uncleaved receptor 24 . Therefore
increased phosphorylation of the receptor b subunit
may not be evident in total cell lysates simply be-
cause of the decreased relative abundance of receptor
b subunits as compared to other transfected cells.
To address the issue of the R86P-mutant insulin
receptor phosphorylation, we used a more sensitive
approach involving immunoprecipitation of the in-
w xsulin receptor by monoclonal antibody 83-7 43 prior
to immunoblotting with an anti-phosphotyrosine anti-
 .body Fig. 4 . Insulin stimulated the phosphorylation
of a 95 kDa band, corresponding to the receptor b
subunit, in CHO cells expressing the WT-IR cDNA
 .lanes 3,4 . Only a tenuous band was evident in CHO
cells transfected with the neomycin-resistance gene
 .alone when stimulated by insulin lanes 1,2 . CHO
cells expressing the R86P substitution had a constitu-
tive increase in the phosphorylation of the receptor b
subunit, with minimal further stimulation caused by
 .insulin addition lanes 5,6 . These data mimic those
w xin human fibroblasts 23 and confirm that the R86P
mutation activates receptor phosphorylation in the
absence of insulin. However the increased basal
 .phosphorylation of the R86P-mutant receptor Fig. 4
was not sufficient to increase phosphorylation of
 .pp185 Figs. 2 and 3 in the absence of insulin.
To determine the relative importance of increased
 .receptor phosphorylation Fig. 4 and normal phos-
phorylation of pp185 in the absence of insulin Fig.
.2 on insulin signaling, we evaluated insulin stimula-
tion of glucose transport in cells transfected with
 .R86-mutant receptors Fig. 5 . As expected, transfec-
tion with the normal insulin receptor cDNA increased
the sensitivity for insulin stimulation of glucose
transport and decreased the dose required for half
maximal stimulation from 285 pM in CHO-NEO
cells to 9.7 pM in CHO-WT-IR cells panel A, Table
.1 . Glucose transport was not increased in the basal
state and remained insulin-sensitive in cells express-
 .ing the R86P mutation panel B , reflecting the pres-
ence of endogenous, normal receptors in CHO cells
w xand the recessive nature of this mutation 2,24 . The
Fig. 4. Effect of insulin on receptor phosphorylation. CHO cells
were incubated for 20 min in the absence or presence of insulin.
Cells were then solubilized in the presence of kinase and phos-
phatase inhibitors and insulin receptors precipitated by MAb
83-7. The immunoprecipitated receptors were separated by SDS-
PAGE, blotted to a polyvinylidene difluoride membrane, and
phosphotyrosine detected using the PY 20 monoclonal antibody.
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Fig. 5. Dose–response curve for insulin stimulation of glucose
transport in CHO cells. CHO cells were incubated 30 min in the
presence of the indicated concentrations of insulin before measur-
ing 3-O-methyl-D-glucose influx for 10 s. Data are means"SD
 .of triplicates. Curves represent the best fit of data to Eq. 1 in
Section 2.4.
sensitivity for insulin stimulation of glucose transport
was not increased by the presence of transfected
R86P-mutant receptors, indicating that in CHO cells
this mutant receptor is unable to stimulate glucose
transport. Transfection with the R86A and R86G
mutant receptor increased the sensitivity to insulin
 .stimulation of glucose transport panel B . However,
the R86A receptors increased this sensitivity much
 .more than R86G receptors panel C . The efficiency
of transfected receptors in mediating the biological
effects of insulin was determined by estimating the
number of receptors occupied by insulin at the ED50
 .for insulin stimulation of glucose transport Table 1 .
The amount of insulin bound at ED did not change50
substantially among CHO-NEO, CHO-WT-IR, and
 .CHO-R86A cells 5.9–7.8 fmolrmg cell protein . By
contrast, CHO cells expressing the R86G receptor
required a higher dose of insulin than CHO-WT-IR
and CHO-R86A cells for half maximal stimulation of
glucose transport and the amount of insulin bound at
ED was four times higher than in other CHO cells.50
This latter result suggests that R86G receptors bind
insulin normally, but have a decreased ability to
couple insulin binding to stimulation of glucose
transport.
4. Discussion
Natural mutations in the insulin receptor gene
cause inherited insulin-resistant syndromes and iden-
tify domains of the receptor essential for receptor
processing, insulin binding, receptor phosphorylation,
and phosphorylation of endogenous substrates. The
R86P mutation of patient Atl-1 with leprechaunism
differs from most of those reported in insulin-re-
sistant patients because it decreases insulin binding,
but also paradoxically activates receptor phosphoryla-
w xtion and signaling of glucose transport 22–24,31 .
This mutation is in close proximity to one of the
w xpredicted insulin binding sites of the receptor 11 .
The studies reported in this paper confirm that the
R86P receptor expressed in CHO cells has impaired
 .insulin binding Fig. 1 and a constitutively increased
 .autophosphorylation Fig. 4 , mimicking previous re-
sults in human fibroblasts homozygous for this muta-
w xtion 22–24 . However, CHO cells expressing the
R86P-mutant receptor had no increased phosphoryla-
tion of high molecular weight substrates of the in-
 .sulin receptor Fig. 2 and normal basal glucose
 .transport Fig. 5 . It is unclear why human fibroblasts
homozygous for the R86P mutation and devoid of
endogenous, normal insulin receptors differed from
CHO cells in having a constitutive increase in glu-
w xcose transport 22 . It is possible that in CHO cells
 .the normal endogenous insulin receptors prevent
activation of glucose transport by the R86P mutant
receptor. This would be consistent with the recessive
nature of this mutation and the normal basal and
insulin-stimulated glucose transport in human fibrob-
lasts obtained from heterozygous parents and express-
w xing both a normal and a mutant insulin receptor 22 .
Since CHO cells with the R86P-mutant receptor failed
to increase the phosphorylation of high molecular
 .weight substrates Fig. 2 , normal receptors may have
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a higher affinity for binding and subtracting intra-
cellular substrates from the mutant receptor, prevent-
ing the propagation of the abnormal insulin signal. A
similar mechanism has been proposed for dominant–
negative mutations in the tyrosine kinase domain of
w xthe insulin receptor 44 . Differential processing of
the R86P-mutant receptor in CHO cells with in-
w xcreased formation of ab uncleaved receptor 24,31
may also reduce the effective concentration of acti-
vated receptor b subunit capable of activating glu-
cose transport.
In addition to confirming and extending our previ-
ous observations with the R86P-mutant insulin recep-
tor, we have examined the effect of two different
substitutions in this position on insulin binding and
stimulation of glucose transport. Introduction of an
 .alanine R86A rather than arginine had no effect on
 .insulin binding Fig. 1 , receptor and substrate phos-
 .phorylation Figs. 2 and 3 , and stimulation of glu-
 .cose transport Fig. 5 . These results confirm that the
86 position of the insulin receptor is tolerant to
w xsubstitution 31 and not directly located in the in-
sulin binding site, as suggested by its lack of conser-
vation in the human and Drosophila insulin receptor
w x45 and in other insulin receptor-like receptors: the
w x w xIGF-I 46 and the insulin-related receptor 47 .
Surprisingly, substitution with glycine resulted in a
receptor capable of binding insulin and autophospho-
rylating, with preserved kinase activity toward intra-
 .cellular substrates Fig. 2 , but with a reduced ability
to couple insulin binding to stimulation of glucose
 .transport Table 1 . This observation, together with
the paradoxical activation of receptor phosphoryla-
tion obtained with the R86P mutation, suggests that
the 86 position of the insulin receptor plays an impor-
tant role in the conformational changes that follows
 .insulin binding possibly to an adjacent domain and
leads to activation of glucose transport. It is possible
that the presence of a side chain which is missing in
.Gly facilitates the interaction with other portions of
the receptor involved in activating glucose transport.
The presence of Pro at the same position would
abolish the insulin binding site and mimic at least in
.part the conformational changes induced by insulin
binding. It will be of interest to determine if analo-
gous substitutions at or around Lys-121 and Asn-281,
whose deletion also activates receptor phosphoryla-
w xtion 27–29 , produce a receptor permanently acti-
vated or uncoupled to stimulation of glucose trans-
port.
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